Nanoparticles Targeting Macrophages as Potential Clinical Therapeutic Agents Against Cancer and Inflammation
With the development of nanotechnology, significant progress has been made in the design, and manufacture of nanoparticles (NPs) for use in clinical treatments. Recent increases in our understanding of the central role of macrophages in the context of inflammation and cancer have reinvigorated inter...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.01998/full |
| _version_ | 1828844535480844288 |
|---|---|
| author | Guorong Hu Mengfei Guo Juanjuan Xu Feng Wu Jinshuo Fan Qi Huang Guanghai Yang Zhilei Lv Xuan Wang Yang Jin |
| author_facet | Guorong Hu Mengfei Guo Juanjuan Xu Feng Wu Jinshuo Fan Qi Huang Guanghai Yang Zhilei Lv Xuan Wang Yang Jin |
| author_sort | Guorong Hu |
| collection | DOAJ |
| description | With the development of nanotechnology, significant progress has been made in the design, and manufacture of nanoparticles (NPs) for use in clinical treatments. Recent increases in our understanding of the central role of macrophages in the context of inflammation and cancer have reinvigorated interest in macrophages as drug targets. Macrophages play an integral role in maintaining the steady state of the immune system and are involved in cancer and inflammation processes. Thus, NPs tailored to accurately target macrophages have the potential to transform disease treatment. Herein, we first present a brief background information of NPs as drug carriers, including but not limited to the types of nanomaterials, their biological properties and their advantages in clinical application. Then, macrophage effector mechanisms and recent NPs-based strategies aimed at targeting macrophages by eliminating or re-educating macrophages in inflammation and cancer are summarized. Additionally, the development of nanocarriers targeting macrophages for disease diagnosis is also discussed. Finally, the significance of macrophage-targeting nanomedicine is highlighted, with the goal of facilitating future clinical translation. |
| first_indexed | 2024-12-12T21:08:36Z |
| format | Article |
| id | doaj.art-6bfccaa02254421bb751fa041847984e |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-12T21:08:36Z |
| publishDate | 2019-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-6bfccaa02254421bb751fa041847984e2022-12-22T00:11:57ZengFrontiers Media S.A.Frontiers in Immunology1664-32242019-08-011010.3389/fimmu.2019.01998475392Nanoparticles Targeting Macrophages as Potential Clinical Therapeutic Agents Against Cancer and InflammationGuorong Hu0Mengfei Guo1Juanjuan Xu2Feng Wu3Jinshuo Fan4Qi Huang5Guanghai Yang6Zhilei Lv7Xuan Wang8Yang Jin9Key Laboratory of Respiratory Diseases of the Ministry of Health, Department of Respiratory and Critical Care Medicine, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, ChinaKey Laboratory of Respiratory Diseases of the Ministry of Health, Department of Respiratory and Critical Care Medicine, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, ChinaKey Laboratory of Respiratory Diseases of the Ministry of Health, Department of Respiratory and Critical Care Medicine, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, ChinaKey Laboratory of Respiratory Diseases of the Ministry of Health, Department of Respiratory and Critical Care Medicine, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, ChinaKey Laboratory of Respiratory Diseases of the Ministry of Health, Department of Respiratory and Critical Care Medicine, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, ChinaKey Laboratory of Respiratory Diseases of the Ministry of Health, Department of Respiratory and Critical Care Medicine, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Thoracic Surgery, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, ChinaKey Laboratory of Respiratory Diseases of the Ministry of Health, Department of Respiratory and Critical Care Medicine, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, ChinaKey Laboratory of Respiratory Diseases of the Ministry of Health, Department of Respiratory and Critical Care Medicine, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, ChinaKey Laboratory of Respiratory Diseases of the Ministry of Health, Department of Respiratory and Critical Care Medicine, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, ChinaWith the development of nanotechnology, significant progress has been made in the design, and manufacture of nanoparticles (NPs) for use in clinical treatments. Recent increases in our understanding of the central role of macrophages in the context of inflammation and cancer have reinvigorated interest in macrophages as drug targets. Macrophages play an integral role in maintaining the steady state of the immune system and are involved in cancer and inflammation processes. Thus, NPs tailored to accurately target macrophages have the potential to transform disease treatment. Herein, we first present a brief background information of NPs as drug carriers, including but not limited to the types of nanomaterials, their biological properties and their advantages in clinical application. Then, macrophage effector mechanisms and recent NPs-based strategies aimed at targeting macrophages by eliminating or re-educating macrophages in inflammation and cancer are summarized. Additionally, the development of nanocarriers targeting macrophages for disease diagnosis is also discussed. Finally, the significance of macrophage-targeting nanomedicine is highlighted, with the goal of facilitating future clinical translation.https://www.frontiersin.org/article/10.3389/fimmu.2019.01998/fullmacrophagesnanoparticlesdrug deliveryinflammationtumor |
| spellingShingle | Guorong Hu Mengfei Guo Juanjuan Xu Feng Wu Jinshuo Fan Qi Huang Guanghai Yang Zhilei Lv Xuan Wang Yang Jin Nanoparticles Targeting Macrophages as Potential Clinical Therapeutic Agents Against Cancer and Inflammation Frontiers in Immunology macrophages nanoparticles drug delivery inflammation tumor |
| title | Nanoparticles Targeting Macrophages as Potential Clinical Therapeutic Agents Against Cancer and Inflammation |
| title_full | Nanoparticles Targeting Macrophages as Potential Clinical Therapeutic Agents Against Cancer and Inflammation |
| title_fullStr | Nanoparticles Targeting Macrophages as Potential Clinical Therapeutic Agents Against Cancer and Inflammation |
| title_full_unstemmed | Nanoparticles Targeting Macrophages as Potential Clinical Therapeutic Agents Against Cancer and Inflammation |
| title_short | Nanoparticles Targeting Macrophages as Potential Clinical Therapeutic Agents Against Cancer and Inflammation |
| title_sort | nanoparticles targeting macrophages as potential clinical therapeutic agents against cancer and inflammation |
| topic | macrophages nanoparticles drug delivery inflammation tumor |
| url | https://www.frontiersin.org/article/10.3389/fimmu.2019.01998/full |
| work_keys_str_mv | AT guoronghu nanoparticlestargetingmacrophagesaspotentialclinicaltherapeuticagentsagainstcancerandinflammation AT mengfeiguo nanoparticlestargetingmacrophagesaspotentialclinicaltherapeuticagentsagainstcancerandinflammation AT juanjuanxu nanoparticlestargetingmacrophagesaspotentialclinicaltherapeuticagentsagainstcancerandinflammation AT fengwu nanoparticlestargetingmacrophagesaspotentialclinicaltherapeuticagentsagainstcancerandinflammation AT jinshuofan nanoparticlestargetingmacrophagesaspotentialclinicaltherapeuticagentsagainstcancerandinflammation AT qihuang nanoparticlestargetingmacrophagesaspotentialclinicaltherapeuticagentsagainstcancerandinflammation AT guanghaiyang nanoparticlestargetingmacrophagesaspotentialclinicaltherapeuticagentsagainstcancerandinflammation AT zhileilv nanoparticlestargetingmacrophagesaspotentialclinicaltherapeuticagentsagainstcancerandinflammation AT xuanwang nanoparticlestargetingmacrophagesaspotentialclinicaltherapeuticagentsagainstcancerandinflammation AT yangjin nanoparticlestargetingmacrophagesaspotentialclinicaltherapeuticagentsagainstcancerandinflammation |